Skip to main content
RMD
NYSE Life Sciences

ResMed Defies GLP-1 Fears, Boosts CPAP Demand with Strategic Physician Outreach

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$255.215
Mkt Cap
$37.179B
52W Low
$199.92
52W High
$293.81
52W Position info
28% above low
Off High info
13% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

RMD sits 28% above its 52-week low of $199.92.

Summary

ResMed is successfully leveraging the weight-loss drug trend, specifically GLP-1s, to boost demand for its CPAP machines, effectively turning a perceived threat into a growth opportunity. This strategy involves targeting primary care physicians who prescribe GLP-1s with educational programs on sleep apnea and CPAP therapy. The company's proactive approach has contributed to robust revenue growth, including an 11% rise in December-quarter revenue, which aligns with the strong Q2 FY26 results reported on January 30, 2026. This strategic adaptation mitigates a significant investor concern regarding the impact of GLP-1 drugs on sleep apnea treatment demand and highlights a new, effective market driver for ResMed's core products.

At the time of this announcement, RMD was trading at $255.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37.2B. The 52-week trading range was $199.92 to $293.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

RMD - Latest Insights

RMD
Oct 29, 2026, 6:11 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $253.00
Real-time Price: $239.53 info
Change: -$13.47 (-5%) info
Market Cap: $33.692B info
RMD
Oct 29, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $252.83
Real-time Price: $239.53 info
Change: -$13.30 (-5%) info
Market Cap: $33.692B info
RMD
Sep 01, 2026, 4:39 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $231.75
Real-time Price: $239.53 info
Change: +$7.78 (+3%) info
Market Cap: $33.692B info
RMD
Sep 01, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $231.36
Real-time Price: $239.53 info
Change: +$8.17 (+4%) info
Market Cap: $33.692B info
RMD
Aug 17, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $220.37
Real-time Price: $239.53 info
Change: +$19.16 (+9%) info
Market Cap: $33.692B info